Acutaas Chemicals Stock Jumps on Q3 Beat, Expansion Plans Spark Valuation Doubts

CHEMICALS
Whalesbook Logo
AuthorRiya Kapoor|Published at:
Acutaas Chemicals Stock Jumps on Q3 Beat, Expansion Plans Spark Valuation Doubts
Overview

Acutaas Chemicals reported a strong Q3FY26 with revenue up 43% and net profit soaring 140%, leading management to raise its FY26 forecast. The company is launching an ambitious expansion into battery chemicals and semiconductors while boosting its CDMO services. However, its recent stock rally has driven valuations well above peers, raising questions about sustained growth and the successful execution of its new ventures.

Strong Q3 Results Boost Acutaas Chemicals

Acutaas Chemicals posted a strong January-March quarter, beating market expectations. Performance was driven by increased contract manufacturing (CDMO) work and significant growth in high-value advanced intermediates. Better product mix and operational efficiency also contributed. Revenue rose 43% year-on-year to ₹393 crore, largely due to a 47% jump in Advanced Pharmaceutical Intermediates. EBITDA surged 119% year-on-year to ₹151 crore. Margins improved sharply to 38.3% from 25% in Q3FY25. Net profit jumped 140% year-on-year to ₹106 crore.

Higher Forecast Amidst Robust Demand

Encouraged by these results, management has increased its financial forecast. The company now targets 30% revenue growth for fiscal year 2026, up from its earlier 25% projection. EBITDA margins are also expected to reach 35%. This optimism is supported by ongoing CDMO expansion, an improving product mix, and strong demand signals across its business.

New Ventures: Battery Chemicals and Semiconductors

Acutaas Chemicals is actively pursuing contract manufacturing (CMO and CDMO) roles to speed up growth in its core pharmaceutical intermediates. The company has four products in its pipeline, expected to contribute from FY27. Its battery chemicals additive segment is set to start by Q4FY26, with full revenue impact expected in FY27. A joint venture for semiconductors in South Korea is planned to start contributing revenue in the second half of FY27.

Analysts Remain Positive Despite Valuation Concerns

Brokerage firms generally maintain a positive view on Acutaas Chemicals. Geojit Investments sees a strong medium-term outlook, pointing to the CDMO pipeline and expanding specialty areas, although the stock currently trades above its ₹2,350 target price. IDBI Capital forecasts a 54% compound annual growth rate (CAGR) for net profit between FY25 and FY28, driven by its CDMO business and other growth drivers. Analysts are optimistic about continued success with key molecules and the expansion of the Ankleshwar facility.

Disclaimer:This content is for informational purposes only and does not constitute financial or investment advice. Readers should consult a SEBI-registered advisor before making decisions. Investments are subject to market risks, and past performance does not guarantee future results. The publisher and authors are not liable for any losses. Accuracy and completeness are not guaranteed, and views expressed may not reflect the publication’s editorial stance.